Showing 4351-4360 of 5627 results for "".
- First Eye Care-Focused SPAC, LifeLong Vision, Launchedhttps://modernod.com/news/first-eye-care-focused-spac-lifelong-vision-to-host-launch-event/2479368/A new multi-billion dollar initiative that aims to provide daily access to eye care through any mobile device officially launched on Wednesday. LifeLong Vision, which is backed by investment banking platform MedHealth Capital, is set to emerge via a Special Purpose Acquisition Company (SPA
- CATS Tonometer Receives FDA Clearance for Disposable Tonometer Prismhttps://modernod.com/news/cats-tonometer-receives-fda-clearance-for-disposable-tonometer-prism/2479364/The CATS-D Disposable Prism, designed to deliver improved IOP measurement accuracy using a sterile, disposable tip replacement for the Goldmann Tonometer, received FDA clearance and will be available for sale in the fall of 2021. “The CATS Tonometer Prism is designed to provide more accura
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration
- Belkin Laser Announces Corporate Name Change to Belkin Visionhttps://modernod.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/Israel-based medical device company Belkin Laser announced that it will begin operating under the new name of Belkin Vision. The name change is a strategic decision that will better reflect the company’s capability to solve future ophthalmic challenges, according to a company stateme
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan
- Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 3 Trial of Zimura in GA Secondary to AMDhttps://modernod.com/news/iveric-bio-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-3-trial-of-zimura-in-ga-secondary-to-amd/2479341/Iveric bio announced that the company received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to a
- CVC Capital Partners VIII to Acquire Majority Stake in Raynerhttps://modernod.com/news/cvc-capital-partners-viii-to-invest-in-rayner/2479340/CVC Capital Partners VIII announced that it has agreed to acquire a majority interest in Rayner, the global ophthalmology business from UK-based private equity firm Phoenix Equity Partners. Terms of the deal were not disclosed. The transaction is expected to close in the third quar
- Nicox to Receive $2 Million from Ocumension as Milestone Payment Under Zerviate Agreementhttps://modernod.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/Nicox announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amend